Clinical Report: Adherence to Procalcitonin-Based Antibiotic Management in China

Overview

This study evaluates adherence to procalcitonin (PCT)-guided antibiotic management in adult infectious disease patients in China. Findings indicate that timely discontinuation of antibiotics based on PCT levels is associated with lower mortality and shorter hospital stays, yet adherence to guidelines remains low.

Background

Antibiotic resistance is a growing concern in China, necessitating effective management strategies for antibiotic therapy. Procalcitonin (PCT) serves as a biomarker to guide antibiotic use, particularly in critically ill patients. Understanding real-world adherence to PCT-based protocols is essential for optimizing treatment and combating antibiotic resistance.

Data Highlights

Key Findings

• 52.3% of patients adhered to PCT criteria for antibiotic discontinuation.
• Lower mortality was observed in compliant patients (13.7% vs. 28.0%, p = 0.023).
• Early discontinuation of antibiotics within 24 hours was linked to shorter EICU stays (7 vs. 18 days).
• Antibiotic duration was significantly reduced in compliant patients (6 vs. 14 days).
• No increase in mortality was noted with early discontinuation of antibiotics.

Clinical Implications

Healthcare providers should prioritize adherence to PCT-guided protocols to optimize antibiotic management in critically ill patients. Implementing regular PCT monitoring could facilitate timely antibiotic discontinuation, potentially reducing hospital stays and antibiotic exposure without compromising patient safety.

Conclusion

The study highlights the need for improved adherence to PCT-based antibiotic management protocols in China, as timely discontinuation is associated with better outcomes. Further research is warranted to enhance compliance and validate these findings.

Related Resources & Content

1. Intensive Care Medicine, 2018 -- Utilizing Procalcitonin to Direct Initial Antibiotic Treatment in ICU Patients with Acute COPD Exacerbations
2. Critical Care (Springer), 2025 -- Cost-effectiveness of procalcitonin-guided antibiotic duration for hospitalized patients with sepsis
3. conexiant -- CAP Antibiotics May Not Benefit Nonsevere COVID-19 Infections
4. Surviving Sepsis Campaign Guidelines 2021 | SCCM
5. Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial | Trials | JAMA
6. Infection — Comparison of Ceftazidime/Avibactam and Polymyxin B for Treating Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae: A Multicenter Real-World Study with Propensity Score Matching
7. Surviving Sepsis Campaign Guidelines 2021 | SCCM
8. Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial | Trials | JAMA | JAMA Network
9. Bacterial infections in patients with COVID-19: the impact of procalcitonin testing on antibiotics prescription in the real world - PMC